Entourage Health Corp. (TSX-V:ENTG) (OTCQX:ETRGF) (FSE:4WE) has signed a deal with the telehealth network HelloMD to expand patient access to healthcare practitioners offering cannabis medical care in Canada.
On Tuesday, the cannabis producer announced the expansion of its Starseed Medicinal services after its patient base grew over 50 per cent since 2019. HelloMD is an American organization that offers online medical consultation with a licensed practitioner that issues medical card licenses for patients.
The company also announced the debut of its digital Patient Treatment Plan which offers dosing guidelines based on recommendations from a health care practitioner. The standardized dosing plan is designed to improve access and overall patient experience.
Starseed also developed a more accurate method for determining cannabinoid profiles by assigning them stars such as one star for high CBD, two stars for balanced concentrations and three stars for high THC.
Patients can now access the virtual resource and platform via the Starseed Blog and Product Guide. Its support services can connect healthcare professionals to keep patients informed and up-to-date.
Entourage is the publicly-traded company of Entourage Brands Corp. –formerly WeedMD RX Inc.– and CannTx Life Sciences Inc.
Its adult-use product portfolio includes Color Cannabis, Saturday Cannabis and Royal City Cannabis Co. The company also has supply agreements with Shoppers Drug Mart and is the exclusive Canadian producer and distributor of Mary’s Medicinals.
Read more: Entourage increases revenue 20% to $12.4M in Q1
Read more: Entourage debuts THC-infused drinks in partnership with popular U.S. brewery
“Expanding our medical platform with enriched patient care, services and new products is reshaping how Canadians access medical cannabis and exemplifies Starseed’s commitment to improving patient outcomes,” Entourage CCO Joseph Mele said.
Mele explained the company is partnering with HelloMD and its network of experienced practitioners to complement its medical team of experts addressing the needs of our growing patient base.
With the launch of our individualized Patient Treatment Plans, clients and providers can build programs based on specific medical cannabis products and dosing schedule being used to meet their needs.”
Entourage stock stayed flat on Tuesday at $0.05 on the Canadian Ventures Exchange.
